SA520411930B1 - وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماته - Google Patents
وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماتهInfo
- Publication number
- SA520411930B1 SA520411930B1 SA520411930A SA520411930A SA520411930B1 SA 520411930 B1 SA520411930 B1 SA 520411930B1 SA 520411930 A SA520411930 A SA 520411930A SA 520411930 A SA520411930 A SA 520411930A SA 520411930 B1 SA520411930 B1 SA 520411930B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- purifying
- compositions
- adherent cells
- cell lysate
- aav viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Manufacturing & Machinery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583035P | 2017-11-08 | 2017-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520411930B1 true SA520411930B1 (ar) | 2025-04-07 |
Family
ID=64362706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520411930A SA520411930B1 (ar) | 2017-11-08 | 2020-05-08 | وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماته |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12168777B2 (https=) |
| EP (2) | EP4585229A3 (https=) |
| JP (2) | JP7587422B2 (https=) |
| KR (1) | KR20200086292A (https=) |
| CN (4) | CN111566220A (https=) |
| AU (2) | AU2018365677C1 (https=) |
| BR (1) | BR112019013268A2 (https=) |
| CA (1) | CA3082136A1 (https=) |
| CL (3) | CL2020001193A1 (https=) |
| CO (1) | CO2020006900A2 (https=) |
| IL (2) | IL314692A (https=) |
| MX (3) | MX2020004830A (https=) |
| MY (1) | MY208779A (https=) |
| SA (1) | SA520411930B1 (https=) |
| SG (1) | SG11202004406VA (https=) |
| TW (1) | TWI827560B (https=) |
| WO (1) | WO2019094253A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| MX2020000713A (es) * | 2017-07-17 | 2020-08-31 | Spark Therapeutics Inc | Metodos de aferesis y sus usos. |
| MX2020004830A (es) | 2017-11-08 | 2020-11-11 | Avexis Inc | Medios y metodo para preparar vectores virales y usos de los mismos. |
| CN112601557B (zh) * | 2018-06-08 | 2025-06-06 | 诺华股份有限公司 | 用于测量药物产品效力的基于细胞的测定 |
| EP3837374A4 (en) * | 2018-08-15 | 2022-06-08 | Biogen MA Inc. | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY |
| WO2020113034A1 (en) * | 2018-11-30 | 2020-06-04 | Avexis, Inc. | Aav viral vectors and uses thereof |
| PL3953377T3 (pl) * | 2019-04-10 | 2026-02-16 | Prevail Therapeutics, Inc. | Terapie genowe zaburzeń lizosomalnych |
| US10801042B1 (en) * | 2019-07-15 | 2020-10-13 | Vigene Biosciences, Inc. | Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus |
| WO2021016075A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| WO2021014428A1 (en) | 2019-07-25 | 2021-01-28 | Novartis Ag | Regulatable expression systems |
| CA3149825A1 (en) * | 2019-08-08 | 2021-02-11 | Biogen Ma Inc. | Potency assays for viral vector production |
| CA3156506A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| KR20220133908A (ko) * | 2020-01-28 | 2022-10-05 | 론자 워커스빌 아이엔씨. | 바이러스 역가를 결정하는 방법 |
| EP4136231A1 (en) | 2020-04-17 | 2023-02-22 | Friedrich Miescher Institute for Biomedical Research | Use of an orphan motif to increase expression of a heterologous transgene |
| RU2742837C1 (ru) * | 2020-06-02 | 2021-02-11 | Общество С Ограниченной Ответственностью "Анабион" | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок SMN1, и ее применение |
| CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
| CN112121179A (zh) * | 2020-09-15 | 2020-12-25 | 山东兴瑞生物科技有限公司 | 一种组合物及其在治疗脊髓性肌萎缩症中的应用 |
| KR20230088393A (ko) * | 2020-10-15 | 2023-06-19 | 프리베일 테라퓨틱스, 인크. | 재조합 아데노 연관 바이러스 조성물 및 이의 제조 방법 |
| CN112251440A (zh) * | 2020-10-29 | 2021-01-22 | 大连理工大学 | 一种CRISPR/Cas9基因载体、其制备方法及应用 |
| WO2022118237A1 (en) | 2020-12-03 | 2022-06-09 | Friedrich Miescher Institute For Biomedical Research | Use of a combination of an orphan motif and cpg density to control expression of a heterologous transgene |
| EP4324907A4 (en) | 2021-04-15 | 2025-06-18 | The University of Tokyo | METHOD FOR PRODUCING VIRUS PARTICLES |
| EP4377459A2 (en) | 2021-07-30 | 2024-06-05 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| WO2023010135A1 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| CA3226803A1 (en) * | 2021-08-04 | 2023-02-09 | Christian Fiedler | Adeno-associated virus separation on a cation exchanger |
| WO2023042104A1 (en) | 2021-09-16 | 2023-03-23 | Novartis Ag | Novel transcription factors |
| CN118119710A (zh) * | 2021-10-15 | 2024-05-31 | 上海天泽云泰生物医药有限公司 | 用于治疗脊髓性肌萎缩的重组腺相关病毒载体 |
| US20250235554A1 (en) | 2021-10-25 | 2025-07-24 | Novartis Ag | Methods for improving adeno-associated virus (aav) delivery |
| WO2023085382A1 (ja) * | 2021-11-12 | 2023-05-19 | Ａｇｃ株式会社 | ウイルスの精製方法 |
| EP4436982A1 (en) | 2021-11-24 | 2024-10-02 | Novartis AG | Modulators of adeno-associated virus transduction and uses thereof |
| US20250353883A1 (en) | 2022-05-06 | 2025-11-20 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
| CA3261865A1 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS |
| CN114990162A (zh) * | 2022-07-18 | 2022-09-02 | 苏州吉纳星辰生物技术有限公司 | 一种降低aav病毒载体生产中质粒残留的方法 |
| WO2024027632A1 (en) * | 2022-08-01 | 2024-02-08 | Skyline Therapeutics (Shanghai) Co., Ltd. | Novel plasmid backbone to reduce dna impurities in raav preparation |
| CN115354071A (zh) * | 2022-08-10 | 2022-11-18 | 上海药明生基医药科技有限公司 | 一种检测重组腺相关病毒宿主细胞dna残留的方法 |
| CN116350801A (zh) | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| CN120835797A (zh) | 2023-03-21 | 2025-10-24 | 豪夫迈·罗氏有限公司 | 用于产生重组aav颗粒制备物的方法 |
| WO2024252182A1 (en) * | 2023-06-08 | 2024-12-12 | Meiragtx Uk Ii Limited | Cation exchange chromatography for aav capture |
| CN120677245A (zh) * | 2024-01-25 | 2025-09-19 | 鼐济医药科技(杭州)有限公司 | Aav载体、载体组合物、嵌合载体和治疗或预防sma的方法 |
| WO2025168663A1 (en) | 2024-02-09 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| WO2025188316A1 (en) * | 2024-03-08 | 2025-09-12 | Jaguar Gene Therapy, Llc | Aav pharmaceutical formulations and methods thereof |
| WO2025190867A1 (en) * | 2024-03-11 | 2025-09-18 | Sartorius Stedim Biotech Gmbh | Two-step intensified cell lysis to release a viral vector |
| WO2025217224A1 (en) * | 2024-04-08 | 2025-10-16 | Advanced Medicine Partners, LLC | Method of manufacture of aav particles |
| KR102915956B1 (ko) * | 2024-04-17 | 2026-01-20 | 한국로봇융합연구원 | 3차원 오비탈 용접로봇 |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| US20260022401A1 (en) | 2024-07-22 | 2026-01-22 | Hoffmann-La Roche Inc. | Novel AAV rep ORFs and Rep polypeptides |
| WO2026028089A1 (en) | 2024-07-29 | 2026-02-05 | Novartis Ag | Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| AU722196B2 (en) | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
| EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP0932418B1 (en) | 1996-09-06 | 2007-12-05 | The Trustees Of The University Of Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
| US6756207B1 (en) | 1997-02-27 | 2004-06-29 | Cellomics, Inc. | System for cell-based screening |
| JP2001514845A (ja) | 1997-09-05 | 2001-09-18 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法 |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| WO2001048155A2 (en) * | 1999-12-29 | 2001-07-05 | Genzyme Corporation | Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| AU2002359284A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| DE602004030327D1 (de) * | 2003-05-21 | 2011-01-13 | Genzyme Corp | Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US20050153446A1 (en) | 2003-11-07 | 2005-07-14 | Steindler Dennis A. | Culturing and differentiating neural precursor cells |
| EP1751275B1 (en) * | 2004-06-01 | 2017-08-16 | Avigen, Inc. | Compositions and methods to prevent aav vector aggregation |
| SI2548560T1 (sl) | 2005-06-23 | 2015-12-31 | Isis Pharmaceuticals, Inc. | Sestavki in postopki za moduliranje izrezovanja smn2 |
| EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| PL2310492T3 (pl) | 2008-06-30 | 2015-12-31 | Janssen Biotech Inc | Różnocowanie pluripotencjalnych komórek macierzystych |
| US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| WO2010071832A1 (en) | 2008-12-19 | 2010-06-24 | Nationwide Children's Hospital | Delivery of polynucleotides across the blood brain barrier using recombinant aav9 |
| US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| PT3305302T (pt) | 2009-06-17 | 2018-12-14 | Biogen Ma Inc | Composições e métodos de modulação de excisões de smn2 em um sujeito |
| CA2784425A1 (en) | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
| DK2529020T3 (en) * | 2010-01-28 | 2018-08-06 | Childrens Hospital Philadelphia | SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| EP2861723A4 (en) | 2012-06-14 | 2016-01-20 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS |
| WO2013190059A1 (en) | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
| AU2013296425B2 (en) | 2012-08-01 | 2018-06-07 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| MX380973B (es) | 2013-05-01 | 2025-03-12 | Genzyme Corp | Composiciones y metodos para tratar la atrofia muscular espinal. |
| EP3020808B1 (en) | 2013-07-11 | 2019-09-11 | Takara Bio Inc. | Method for manufacturing adeno-associated virus |
| EP3024497B1 (en) | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| LT3702466T (lt) | 2013-08-27 | 2023-02-27 | Research Institute At Nationwide Children's Hospital | Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
| EP2933335A1 (en) | 2014-04-18 | 2015-10-21 | Genethon | A method of treating peripheral neuropathies and motor neuron diseases |
| US10526583B2 (en) * | 2014-07-02 | 2020-01-07 | University Of Florida Research Foundation, Incorporated | Compositions and methods for purifying recombinant adeno-associated virus |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| CN107249646B (zh) | 2014-12-16 | 2021-06-29 | 内布拉斯加大学董事会 | 用于青少年巴滕病的基因疗法 |
| EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
| EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
| EP3387138B1 (en) * | 2015-12-11 | 2022-01-26 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| BR112018070256A2 (pt) * | 2016-03-31 | 2019-01-29 | Spark Therapeutics, Inc. | processo de fabricação de raav totalmente escalável à base de colunas |
| IL305449B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous type ii diabetes |
| EP3299456A1 (en) | 2016-09-26 | 2018-03-28 | Université de Strasbourg | Recombinant dgkk gene for fragile x syndrome gene therapy |
| BR112019009834B1 (pt) | 2016-11-17 | 2022-05-17 | Ohio State Innovation Foundation | Vetor viral adeno-associado recombinante (raav), vírus, composição farmacêutica e uso de um vetor raav |
| US20200370069A1 (en) | 2017-07-08 | 2020-11-26 | Genethon | Treatment of spinal muscular atrophy |
| MX2020004830A (es) | 2017-11-08 | 2020-11-11 | Avexis Inc | Medios y metodo para preparar vectores virales y usos de los mismos. |
| CN112601557B (zh) | 2018-06-08 | 2025-06-06 | 诺华股份有限公司 | 用于测量药物产品效力的基于细胞的测定 |
-
2018
- 2018-11-01 MX MX2020004830A patent/MX2020004830A/es unknown
- 2018-11-01 CN CN201880085757.1A patent/CN111566220A/zh active Pending
- 2018-11-01 EP EP25159502.1A patent/EP4585229A3/en active Pending
- 2018-11-01 CN CN202411444917.0A patent/CN119033965A/zh active Pending
- 2018-11-01 SG SG11202004406VA patent/SG11202004406VA/en unknown
- 2018-11-01 BR BR112019013268-6A patent/BR112019013268A2/pt not_active Application Discontinuation
- 2018-11-01 EP EP18804830.0A patent/EP3707264A1/en active Pending
- 2018-11-01 CN CN202510662244.4A patent/CN120505370A/zh active Pending
- 2018-11-01 IL IL314692A patent/IL314692A/en unknown
- 2018-11-01 IL IL274430A patent/IL274430B2/en unknown
- 2018-11-01 US US16/761,869 patent/US12168777B2/en active Active
- 2018-11-01 AU AU2018365677A patent/AU2018365677C1/en active Active
- 2018-11-01 CN CN202510662252.9A patent/CN120501895A/zh active Pending
- 2018-11-01 CA CA3082136A patent/CA3082136A1/en active Pending
- 2018-11-01 TW TW107138852A patent/TWI827560B/zh active
- 2018-11-01 MY MYPI2020002052A patent/MY208779A/en unknown
- 2018-11-01 KR KR1020207014865A patent/KR20200086292A/ko not_active Ceased
- 2018-11-01 JP JP2020544560A patent/JP7587422B2/ja active Active
- 2018-11-01 WO PCT/US2018/058744 patent/WO2019094253A1/en not_active Ceased
-
2020
- 2020-05-06 CL CL2020001193A patent/CL2020001193A1/es unknown
- 2020-05-08 SA SA520411930A patent/SA520411930B1/ar unknown
- 2020-06-04 CO CONC2020/0006900A patent/CO2020006900A2/es unknown
- 2020-07-13 MX MX2025001503A patent/MX2025001503A/es unknown
- 2020-07-13 MX MX2025009360A patent/MX2025009360A/es unknown
-
2024
- 2024-09-02 JP JP2024150419A patent/JP2025017361A/ja active Pending
- 2024-11-08 US US18/940,967 patent/US20250066813A1/en active Pending
- 2024-12-26 CL CL2024004045A patent/CL2024004045A1/es unknown
-
2025
- 2025-05-14 AU AU2025203480A patent/AU2025203480B2/en active Active
- 2025-05-15 CL CL2025001440A patent/CL2025001440A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411930B1 (ar) | وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماته | |
| WO2017160360A3 (en) | Scalable purification method for aav9 | |
| HRP20211882T1 (hr) | Protutijela protiv cd40 i njihova upotreba | |
| MX2023012498A (es) | Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico. | |
| WO2012171026A3 (en) | Methods for high yield virus production | |
| BR112018016944A2 (pt) | composições funcionais derivadas de feijão mungo | |
| KR20120083896A (ko) | 아데노바이러스 입자의 정제 방법 | |
| PH12016501421A1 (en) | PROCESS FOR EFFICIENT PURIFICATION OF NEUTRAL HUMAN MILK OLIGOSACCHARIDES (HMOs) FROM MICROBIAL FERMENTATION | |
| MX2012003654A (es) | Metodos de produccion de glucoproteinas en cultivos de celulas de mamiferos usando glucocorticoides. | |
| MX2019015304A (es) | Amortiguador de lavado para cromatografia de intercambio cationico. | |
| RU2015135473A (ru) | Способ получения аденовируса | |
| MX2019008914A (es) | Purificacion de iduronato-2-sulfatasa. | |
| WO2016030489A3 (en) | A process for the production of adenovirus | |
| Jungblut et al. | Standardized preparation of single-cell suspensions from mouse lung tissue using the gentleMACS Dissociator | |
| CN106574252A (zh) | 从细胞培养物中纯化脊髓灰质炎病毒的方法 | |
| BR112017023624A2 (pt) | método de cultivo em pequena escala para células em suspensão | |
| CR20200507A (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| EA201101532A1 (ru) | Способ получения частиц рекомбинантного полиомавирусного вектора | |
| HRP20200710T1 (hr) | Novi postupak za efikasno pročišćavanje humanog serumskog albumina | |
| CO7230343A2 (es) | Método para expresar altamente protéinas recombinantes de bacterias diseñadas por ingeniería y uso de las mismas | |
| Chen et al. | Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system | |
| Nasimuzzaman et al. | Production and purification of baculovirus for gene therapy application | |
| Cai et al. | Development and characterization of a cDNA-launch recombinant simian hemorrhagic fever virus expressing enhanced green fluorescent protein: ORF 2b’is not required for in vitro virus replication | |
| WO2020067648A3 (ko) | 수지상세포를 이용한 면역 소재의 면역증진 효과 평가방법 및 면역 소재 스크리닝 방법 | |
| MY192147A (en) | Method for obtaining high-yield, stable expression cell clones and antibody molecules obtained thereby |